Literature DB >> 28966081

Patterns of care and outcomes of proton and eye plaque brachytherapy for uveal melanoma: Review of the National Cancer Database.

Alexander J Lin1, Yuan J Rao1, Sahaja Acharya1, Julie Schwarz1, Prabakar Kumar Rao2, Perry Grigsby3.   

Abstract

PURPOSE: To examine national practice patterns and outcomes of eye plaque brachytherapy compared to proton external beam radiotherapy in the treatment of choroid melanoma. METHODS AND MATERIALS: Demographic and clinical data for 1224 patients with choroid melanoma treated with either brachytherapy or proton beam therapy from 2004 to 2013 were obtained from the National Cancer Database. Logistic regression and propensity score matching was used to create a 1:1 matched cohort. Kaplan-Meier and Cox regression analyses were performed to evaluate survival in brachytherapy and proton groups.
RESULTS: Median followup was 37 and 29 months for brachytherapy and protons, respectively. Most patients were treated with brachytherapy (n = 996) vs. protons (n = 228). Proton patients came from more urban, affluent, and educated zip codes, and they were more likely to be treated at an academic center (all p < 0.004). In the propensity-score matched cohort, 2-year overall survival was 97% vs. 93%, and 5-year overall survival was 77% vs. 51% for brachytherapy and protons, respectively (p = 0.008). Multivariate Cox regression found older age (hazard ratio [HR] = 1.06, 95% confidence interval (CI) = 1.03-1.09), larger tumor diameter (12-18 mm, HR = 2.48, 95% CI = 1.40-4.42, >18 mm, HR = 6.41, 95% CI = 1.45-28.35), and protons (HR = 1.89, 95% CI = 1.06-3.37) were negative prognosticators of survival.
CONCLUSIONS: Patients selected for proton treatment have inferior survival outcomes compared to brachytherapy in this retrospective analysis. There may be unaccounted variables that influence survival, warranting further prospective studies.
Copyright © 2017 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Choroid melanoma; National Cancer Database; Plaque brachytherapy; Proton therapy; Uveal melanoma

Mesh:

Substances:

Year:  2017        PMID: 28966081     DOI: 10.1016/j.brachy.2017.07.014

Source DB:  PubMed          Journal:  Brachytherapy        ISSN: 1538-4721            Impact factor:   2.362


  6 in total

1.  Stereotactic radiotherapy for choroidal melanomas by means of HybridArc™ : Physics and technique of linac-based photon beam therapy.

Authors:  Markus Wösle; Lothar Krause; Shanthala Sreenivasa; Dirk Vordermark; Ilja F Ciernik
Journal:  Strahlenther Onkol       Date:  2018-08-16       Impact factor: 3.621

2.  Elevated VEGF-A & PLGF concentration in aqueous humor of patients with uveal melanoma following Iodine-125 plaque radiotherapy.

Authors:  Meng-Xi Chen; Yue-Ming Liu; Yang Li; Xuan Yang; Wen-Bin Wei
Journal:  Int J Ophthalmol       Date:  2020-04-18       Impact factor: 1.779

3.  The Economic Value of MR-Imaging for Uveal Melanoma.

Authors:  Lorna Grech Fonk; Teresa A Ferreira; Andrew G Webb; Gregorius P M Luyten; Jan-Willem M Beenakker
Journal:  Clin Ophthalmol       Date:  2020-04-28

Review 4.  X-change symposium: status and future of modern radiation oncology-from technology to biology.

Authors:  Stefanie Corradini; Maximilian Niyazi; Dirk Verellen; Vincenzo Valentini; Seán Walsh; Anca-L Grosu; Kirsten Lauber; Amato Giaccia; Kristian Unger; Jürgen Debus; Bradley R Pieters; Matthias Guckenberger; Suresh Senan; Wilfried Budach; Roland Rad; Julia Mayerle; Claus Belka
Journal:  Radiat Oncol       Date:  2021-02-04       Impact factor: 4.309

5.  Three-year outcomes of uveal melanoma treated with intra-operative ultrasound-guided iodine-125 brachytherapy using custom-built eye plaques.

Authors:  Andrew J Wong; Bin S Teh; Brandon T Nguyen; Ramiro Pino; Maria E Bretana; Eric H Bernicker; Patricia Chevez-Barrios; E Brian Butler; Amy C Schefler
Journal:  J Contemp Brachytherapy       Date:  2022-04-11

6.  Contemporary trends in management of uveal melanoma.

Authors:  Neil Chevli; Raed J Zuhour; Jay A Messer; Waqar Haque; Amy C Schefler; Eric H Bernicker; Patricia Chevez-Barrios; Andrew M Farach; E Brian Butler; Bin S Teh
Journal:  J Contemp Brachytherapy       Date:  2022-04-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.